Table 2. Clinical and laboratory features of the neurosyphilis patients enrolled in this study.
| Asymptomaticb | Symptomatic | ||||
| Meningovascular | Paretic | Tabetic | Ocular | ||
| No. of Cases | 40 | 4 | 39 | 8 | 12 |
| Male No. (%) | 23 (57.5) | 4 (100) | 35 (89.7) | 5(62.5) | 6(50) |
| Age (range), y | 51.5(25–75) | 47.5(41–54) | 50(37–71) | 48(34–59) | 50(39–66) |
| a Duration (range), mo | 2(0.1–12) | 8(6–12) | 12(0.5–60) | 12(2–72) | 12(6–36) |
| Baseline plasma RPR(range) | 64(1–512) | 48(2–128) | 64(8–512) | 32(2–128) | 96(16–256) |
| CSF protein, mg/dl(range) | 39.6(20–87) | 50.5(22.3–100.5) | 59.5(20–186) | 33.9(14–64) | 39.5(20–74) |
| CSF-WBC, cells/µl (range) | 4.2(0–84) | 40.7(5.6–73.7) | 5(0–97.9) | 19.8(2–145.2) | 2.75(1–86.9) |
| CSF VDRL (+) (%) | 40(100) | 4(100) | 37(94.9) | 8(100) | 10(83.3) |
| CSF VDRL (−) and CSF-TPPA (+) (%) | 0(0) | 0(0) | 2(5.1) | 0(0) | 2(16.7) |
Data are given as median (range), or frequencies.
a
“Duration of asymptomatic neurosyphilis” means the period between the patient's high risk behaviors which may be infected with T. pallidum and the confirmed neurosyphilis. “Duration of symptomatic neurosyphilis” means the duration of clinical manifestations;
b
includes 16 subjects with secondary syphilis, 2 subjects with early latent and 22 subjects with latent or unknown duration.